Abstract
SET (SE translocation, SET) is an evolutionarily conserved gene broadly expressed in various human tissues, especially in the gonadal and neural system. As a multitasking protein, SET is involved in essential cell processes such as histone modification, chromatin remodeling, DNA repair, gene transcription, and androgen synthesis. Recent studies showed that SET is overexpressed in breast cancers, ovary cancers and a variety of other malignancies. The strong correlation between SET expression levels and survival of ovarian cancer patients, and SET-mediated activation of androgen synthesis, strongly indicated that this factor may play a significant role in gynecologic cancers. Here, we summarized data pertaining to the pathological implications of SET in tumorigenesis and cancer progression. We analyzed how SET, through the PP2A-dependent and PP2A-independent pathways, may regulate different cell functions. Potential interactions among these pathways and future studies on SET’s oncogenic activities are also discussed.
Keywords: SET, PP2A, I2PP2A, INHAT, gynecologic cancer, steroid hormone, histone chaperone.
Current Drug Targets
Title:Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Volume: 18 Issue: 10
Author(s): Shi-wen Jiang, Siliang Xu, Haibin Chen, Jiayin Liu*Ping Duan
Affiliation:
- The State Key Laboratory of Reproductive Medicine, Center of Clinical Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029,China
Keywords: SET, PP2A, I2PP2A, INHAT, gynecologic cancer, steroid hormone, histone chaperone.
Abstract: SET (SE translocation, SET) is an evolutionarily conserved gene broadly expressed in various human tissues, especially in the gonadal and neural system. As a multitasking protein, SET is involved in essential cell processes such as histone modification, chromatin remodeling, DNA repair, gene transcription, and androgen synthesis. Recent studies showed that SET is overexpressed in breast cancers, ovary cancers and a variety of other malignancies. The strong correlation between SET expression levels and survival of ovarian cancer patients, and SET-mediated activation of androgen synthesis, strongly indicated that this factor may play a significant role in gynecologic cancers. Here, we summarized data pertaining to the pathological implications of SET in tumorigenesis and cancer progression. We analyzed how SET, through the PP2A-dependent and PP2A-independent pathways, may regulate different cell functions. Potential interactions among these pathways and future studies on SET’s oncogenic activities are also discussed.
Export Options
About this article
Cite this article as:
Jiang Shi-wen , Xu Siliang, Chen Haibin, Liu Jiayin *, Duan Ping, Oncogenic Role of SET/I2PP2A for Gynecologic Cancers, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170328114506
DOI https://dx.doi.org/10.2174/1389450118666170328114506 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alternative Splicing Regulates Pluripotent State in Pluripotent Stem Cells
Current Stem Cell Research & Therapy Positron Emission Tomography Imaging of Tumor Hypoxia
Current Medical Imaging Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer
Current Drug Research Reviews Neuroproteomics and the Detection of Regulatory Phosphosites
Current Proteomics Anti-cancer Therapies in High Grade Gliomas
Current Proteomics Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Anti-Infective Protective Properties of S100 Calgranulins
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design New Scope of Targeted Therapies in Lung Carcinoma
Mini-Reviews in Medicinal Chemistry Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets H+-myo-Inositol Transporter SLC2A13 as a Potential Marker for Cancer Stem Cells in an Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Multimodal HDAC Inhibitors with Improved Anticancer Activity
Current Cancer Drug Targets